Araris, Novago and Tolremo are nominated for Strüngmann Award

Au, Schlieren, and Basel, Switzerland — A Swiss company will receive the Strüngmann Award for revolutionary technologies in the life science sector in the DACH region in 2025. The nominees are Araris in Au, NovaGo in Schlieren, and Tolremo in Basel.

Three companies from Switzerland have been nominated for the Strüngmann Award, which is being presented for the second time this year. Established in 2024, the award honors outstanding entrepreneurs establishing revolutionary technologies in the life sciences sector in the DACH region. According to a press release, the nominees are Araris Biotech in Au, NovaGo Therapeutics in Schlieren, and TOLREMO Therapeutics in Basel. The winning team will be announced on July 3 and will receive 100,000 euros in prize money.

The founding team of Araris Biotech was nominated. This spin-off of the Paul Scherrer Institute (PSI) is developing a new generation of drugs that are transforming the concept of targeted cancer therapy. These drugs could also be used in other medical fields in the future. The nominees are CEO Dragan Grabulovski, CSO Philipp Spycher, and CTO Isabella Attinger-Toller.

Professor Martin E. Schwab was nominated at NovaGo Therapeutics, a member of the Bio-Technopark Schlieren-Zurich. The neuroscientist serves as Chief Scientific Officer (CSO) and co-founded the company in 2015. The biotech company specializes in antibody-based therapies for nerve and blood vessel regeneration. Its main program focuses on treating acute spinal cord injuries.

Stefanie Flückiger-Mangual founded and is the CEO of TOLREMO Therapeutics in Basel. The company is pursuing a new, comprehensive approach to overcoming resistance to cancer drugs.

“We are convinced of the extraordinary talent in the life sciences sector in the DACH region, and we would like to use this award to highlight and promote both innovative ideas and their successful implementation,” said Andreas and Thomas Strüngmann.

(Translated punkt4 Limmatstadt)